Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP.


Glutamate regulates the function of central nervous system (CNS), in part, through the cAMP and/or IP3/DAG second messenger-associated metabotropic glutamate receptors (mGluRs). The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) has been extensively used to elucidate potential physiological and pathophysiological functions of mGluR5. Unfortunately, recent evidence indicates significant non-specific actions of MPEP, including inhibition of NMDA receptors. In contrast, in vivo and in vitro characterization of the newer mGluR5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) indicates that it is more highly selective for mGluR5 over mGluR1, has no effect on other mGluR subtypes, and has fewer off-target effects than MPEP. This article reviews literature on both of these mGluR5 antagonists, which suggests their possible utility in neurodegeneration, addiction, anxiety and pain management.

Citations per Year

1,603 Citations

Semantic Scholar estimates that this publication has 1,603 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Lea2006MetabotropicGR, title={Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP.}, author={Paul M Lea and Alan I. Faden}, journal={CNS drug reviews}, year={2006}, volume={12 2}, pages={149-66} }